Please assess the completion status of the following clinical trial:

Trial Title: Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 75 years~2. Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders - IV-TR)~3. Presence of excessive sweating by self-report~4. The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption~5. Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative~6. Excessive sweating has persisted for at least 4 weeks prior to baseline assessment~7. The excessive sweating is rated by the patient as at least moderately bothersome.~8. Episodes of excessive sweating occur at least twice a week for last 4 weeks~Exclusion Criteria:~1. Presence of another known disease that could potentially cause excessive sweating~2. Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past~3. Blood pressure less than 110 mm Hg systolic at the screening or baseline visits~4. Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).~5. Current antihypertensive treatment~6. History of significant cardiac disease, including coronary artery disease~7. Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)~8. History of priapism (persistent and painful erection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- terazosin (Type: EXPERIMENTAL): open-label treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).